Celldex Therapeutics, Inc. (Nasdaq: CLDX), an antibody-based combination immunotherapy company, today announced that CDX-1127, a preclinical therapeutic antibody program for oncology indications, will be the subject of a poster presentation at the 2010 American Association for Cancer Research (AACR) 101st Annual Meeting in Washington, DC on Wednesday, April 21, 2010. The presentation (poster #5343) is entitled “Development of Novel Anti-CD27 Human Antibodies with Therapeutic Potential”. The presentation is scheduled from 8:00 a.m. to 11:00 a.m. EDT in Exhibit Hall A-C at the Walter E. Washington Convention Center. Celldex will release data before U.S. financial markets open on Wednesday, April 21, 2010.

About Celldex Therapeutics, Inc.

Celldex Therapeutics is the first antibody-based combination immunotherapy company. Celldex has a pipeline of drug candidates in development for the treatment of cancer and other difficult-to-treat diseases based on its antibody focused Precision Targeted Immunotherapy Platform. The PTI Platform is a complementary portfolio of monoclonal antibodies, antibody-targeted vaccines and immunomodulators used in optimal combinations to create novel disease-specific drug candidates. For more information, please visit http://www.celldextherapeutics.com.